Leerink Partnrs Issues Positive Outlook for Hologic Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Partnrs raised their FY2025 earnings per share (EPS) estimates for Hologic in a research note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings of $4.31 per share for the year, up from their previous forecast of $4.27. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.14 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $1.20 EPS, Q4 2026 earnings at $1.21 EPS and FY2026 earnings at $4.69 EPS.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.89 EPS.

HOLX has been the subject of a number of other reports. Mizuho decreased their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Leerink Partners cut their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Royal Bank of Canada raised their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Wolfe Research initiated coverage on shares of Hologic in a research report on Friday. They issued a “peer perform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.50.

Hologic Trading Down 1.6 %

Shares of HOLX stock opened at $72.44 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market capitalization of $16.44 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 2.38 and a beta of 0.96. Hologic has a 52-week low of $70.24 and a 52-week high of $84.67. The company has a 50-day simple moving average of $79.17 and a two-hundred day simple moving average of $78.64.

Hedge Funds Weigh In On Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Prentiss Smith & Co. Inc. lifted its position in Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Empirical Finance LLC boosted its stake in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares in the last quarter. Finally, Wedmont Private Capital grew its holdings in shares of Hologic by 3.7% during the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 162 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.75% of the stock is owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.